LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.27 0.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.22

Massimo

31.3

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.069 50.102
EPS	0.79
Margine di Profitto	42.663
Dipendenti	182
EBITDA	2M 83M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+3.75% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	285M 3.8B
Apertura precedente	31.21
Chiusura precedente	31.27

Notizie sul Sentiment di mercato

By Acuity

78%

22%

306 / 344 Classifica in Healthcare

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 giu 2026, 23:38 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 giu 2026, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 giu 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 giu 2026, 21:53 UTC

Discorsi di Mercato

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 giu 2026, 21:22 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

1 giu 2026, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 giu 2026, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 giu 2026, 19:40 UTC

Discorsi di Mercato

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 giu 2026, 19:28 UTC

Discorsi di Mercato

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 giu 2026, 19:01 UTC

Discorsi di Mercato

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 giu 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 giu 2026, 18:54 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 giu 2026, 18:33 UTC

Discorsi di Mercato

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 giu 2026, 18:32 UTC

Discorsi di Mercato

Precious Metals Fall to Start June -- Market Talk

1 giu 2026, 18:00 UTC

Acquisizioni, Fusioni, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 17:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

3.75% in crescita

Previsioni per 12 mesi

Media 32.4 USD 3.75%

Alto 35 USD

Basso 31.5 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

306 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.